EHI
SRPT icon

Eagle Health Investments’s Sarepta Therapeutics SRPT Stock Holding History

Eagle Health Investments’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-103,256
Closed -$13.4M – 29
2024
Q1 		$13.4M Sell
103,256
-86,100
-45% -$10.5M 2.48% 17
2023
Q4 		$18.3M Buy
189,356
+15,144
+9% +$1.45M 3.71% 12
2023
Q3 		$21.1M Buy
174,212
+76,872
+79% +$8.69M 4.65% 11
2023
Q2 		$11.1M Sell
97,340
-41,300
-30% -$5.33M 2.08% 18
2023
Q1 		$19.1M Buy
+138,640
New +$18M 3.72% 14

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Eagle Health Investments's SRPT Position: Q2 2024 in Review

Eagle Health Investments sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 103,256 shares — an estimated $13.4M sold.

Eagle Health Investments first reported a position in SRPT in Q1 2023 and held it in 5 quarters. The position peaked at $21.1M in Q3 2023. 484 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

  • Eagle Health Investments reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Eagle Health Investments sold 103,256 Sarepta Therapeutics shares in Q2 2024, an estimated $13.4M.
  • Eagle Health Investments first reported a position in Sarepta Therapeutics in Q1 2023 and held it in 5 quarters.
  • Eagle Health Investments's Sarepta Therapeutics position peaked at $21.1M in Q3 2023.
  • 484 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Eagle Health Investments's 13F filing for Q2 2024, filed 13 Aug 2024.